Open AccessAdjuvants in tuberculosis vaccine development
Author(s) -
MorenoMendieta Silvia A.,
RochaZavaleta Leticia,
RodriguezSanoja Romina
Publication year - 2010
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2009.00629.x
Subject(s) - tuberculosis , biology , tuberculosis vaccines , bcg vaccine , mycobacterium tuberculosis , virology , vaccination , immunology , microbiology and biotechnology , medicine , pathology
Tuberculosis remains a major public health problem around the world. Because the Mycobacterium bovis Bacilli–Calmette–Guerin (BCG) vaccine fails to protect adults from pulmonary tuberculosis, there is an urgent need for improved vaccine formulations. Unlike BCG, recombinant vaccines purified from bacterial expression vectors, as well as naked DNA, require an additional adjuvant. Recent improvements in our understanding of disease immunopathology, together with advances in biochemical and molecular techniques, have permitted the successful development of promising tuberculosis vaccine delivery and adjuvant combinations for human use. Here, we summarize the current state of adjuvant development and its impact on tuberculosis vaccine progress.